Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
Accepting patients
QUINTESSENTIAL-2
Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- CD3
- BCMA
- Phase 1
- Has results
Accepting patients
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- BCMA
- Phase 3
Accepting patients
Sonrotoclax (BGB-11417)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
CaMMouflage
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
- CAR T Cell (Allogeneic)
- BCMA
- Phase 1
- Has results
Accepting patients
TRIgnite-1
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
- T Cell
- Trispecific Antibody
- CD38
- BCMA
- Phase 1
- Has results
Accepting patients
FASTER
Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)
- Bispecific Antibody
- Autologous Stem Cell Transplant
- BCMA
- Phase 2
- Proteasome Inhibitor
- Randomization
- Minimal Residual Disease (MRD)
- Phase 2
Not yet accepting
RECLAIM
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- BCMA
- Post-CAR T
- Phase 2
Not yet accepting
FT836 CAR T-cell Therapy
Phase I Study of FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell (Allogeneic)
- T Cell (Allogeneic)
- MICA
- MICB
- Phase 1
1 hidden based on your filters.Show All